MUMBAI, India, Jan. 29, 2026 /PRNewswire/ — Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company,MUMBAI, India, Jan. 29, 2026 /PRNewswire/ — Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company,

Piramal Pharma Limited Announces Results for Q3 and 9M FY26

2026/01/29 13:45
8 min read

MUMBAI, India, Jan. 29, 2026 /PRNewswire/ — Piramal Pharma Limited (NSE: PPLPHARMA) (BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced its standalone and consolidated results for the Third Quarter (Q3) and Nine Month (9M) ended 31st December 2025.

Consolidated Financial Highlights

(in Crores or as stated)

Particulars

Q3FY26

Q3FY25

YoY %

9MFY26

9MFY25

YoY %

Revenue from Operations

2,140

2,204

(3) %

6,117

6,397

(4) %

   CDMO

1,166

1,278

(9) %

3,207

3,659

(12) %

   CHG

668

654

2 %

1,948

1,928

1 %

   PCH

334

278

20 %

954

819

16 %

EBITDA

239

350

(32) %

628

977

(36) %

EBITDA Margin

11 %

16 %

10 %

15 %

PAT Before Expectational Item

(95)

4

NM

(297)

(62)

NM

Exceptional Item

(41)

NM

(20)

NM

PAT After Expectational Item

(136)

4

NM

(317)

(62)

NM

Key Highlights for Q3 and 9M FY26

  • Revenue growth in Q3/9M FY26 was impacted by inventory destocking in one large on-patent commercial product by customer, slower early-stage order inflows in H1FY26 due to inconsistent recovery in US biopharma funding along with uncertainties on global trade policies, and regulatory delays in inhalation anesthesia for ex-US markets from Digwal facility.
  • EBITDA Margin Despite lower revenues, impact on EBITDA was partly offset by our efforts towards cost optimization and operational excellence.
  • Seeing significant pick-up in RFPs with early signs of recovery in order inflows since October 2025 on the back of improved biopharma funding and increased M&A activities in the US.
  • Growth Capex – US$ 90Mn investment to expand Lexington and Riverview facilities, on track. Seeing good customer interest.

Nandini Piramal, Chairperson, Piramal Pharma Limited, said, “FY26 has been a muted year for the Company due to impact of inventory destocking and slower early-stage order inflows in H1FY26 in our CDMO business. However, in recent time, we are seeing early signs of recovery with pick-up in RFPs and order inflows on the back of improved biopharma funding and increased M&A activities in the US healthcare space. In our CHG business, we are investing in new products and expanding our presence in the ex-US markets. Acquiring niche brand like Kenalog, which is synergetic to our current business, is an important step in this direction. Our consumer business continues to outperform in its representative markets with robust growth in our power brands.

Despite the slower growth in FY26, we continue to believe in long term growth prospects of our businesses and back them with timely investments in capacities and capabilities. Q4 has been historically the strongest quarter for the Company, and we expect this trend to continue this year as well.”

Key Business Highlights for Q3/9M FY26

Contract Development and Manufacturing Organization (CDMO):

  • Biopharma funding in H2CY25 has shown signs of recovery with funding in H2CY25 close to double vs. H1CY25 and higher by over 50% vs H2CY24. Although, on full year basis CY25 funding was flat vs. CY24.
  • Seeing significant improvement in RFPs along with uptick in order inflow since October 2025. Growth in orders from both large pharma and mid-size biotech companies.
  • RFP/RFI trends for our overseas facilities with differentiated capabilities remained healthy. These sites have superior gross margin and scale up at these facilities can drive profitability going forward.
  • Sustenance of biopharma funding along with faster decision making by the customers would be the key to healthy growth in FY27.
  • US$ 90Mn investment to expand Lexington and Riverview facilities, on track. Seeing good customer interest for our North America sites, especially from those looking for onshoring.
  • Maintained our Best-in-Class Quality Track Record – Successfully closed 30 regulatory inspections, including 2 USFDA inspections in 9MFY26. Continue to maintain our ‘Zero OAI’ status.

Complex Hospital Generics (CHG):

  • Acquired Kenalog® –
    • Entered into an agreement to acquire Kenalog® from Bristol-Myers Squibb in an all-cash deal for upfront consideration of US$ 35Mn, and contingent consideration of up to US$ 65Mn.
    • Kenalog® is a branded commercial injectable product with complex manufacturing requirements, complementing the CHG product portfolio. It is expected to generate EBITDA margin in-line with existing CHG business margins.
  • Inhalation Anesthesia (IA) –
    • Growing faster than market in the mature US Sevoflurane market with value market share of 47% – up from 44% in MAT Mar’24. (Source:- IQVIA)
    • Initiated Sevoflurane supplies from lower cost Digwal facility in RoW markets. However initial pick-up lower than expected due to regulatory delays.
  • Intrathecal Therapy – Supply impacted in Q2FY26 have normalized. Maintained our #1 Rank in intrathecal Baclofen in the US with 75% value market share. (Source:- IQVIA)
  • Injectable Pain Management – Initiatives to resolve supply constraints starting to yield results.

Piramal Consumer Healthcare (PCH):

  • Power Brands grew strength to strength with 30% / 23% YoY growth during Q3 / 9M FY26, contributing to 51% of total PCH sales. Growth was primarily driven by Little’s, Lacto Calamine, CIR, and i-range.
  • New Product Launches – Launched 31 new products and SKUs in 9M FY26.
  • Invested about 12% of PCH sales in media and promotions in 9M FY26.
  • E-commerce sales grew at 50% rate YoY in 9M FY26, contributing about 26% to PCH sales. More than 40% of e-commerce sales coming from quick commerce.
  • Optimizing Portfolio and Distribution Channel Mix – Focused efforts to grow profitable brands and distribution channels with better margins.

Consolidated Profit and Loss Statement

(in Crores or as stated)

Particulars

Quarterly

Nine Months

Q3FY26

Q3FY25

YoY %

Q2FY26

QoQ %

9MFY26

9MFY25

YoY %

Revenue from Operations

2,140

2,204

(3) %

2,044

5 %

6,117

6,397

(4) %

Other Income

43

12

256 %

66

(34) %

167

93

80 %

Total Income

2,183

2,216

(2) %

2,109

3 %

6,285

6,490

(3) %

Material Cost

786

806

(2) %

703

12 %

2,183

2,277

(4) %

Employee Expenses

600

556

8 %

611

(2) %

1,830

1,695

8 %

Other Expenses

558

504

11 %

571

(2) %

1,643

1,541

7 %

EBITDA

239

350

(32) %

224

7 %

628

977

(36) %

Interest Expenses

89

103

(14) %

82

8 %

258

318

(19) %

Depreciation

213

197

8 %

203

5 %

613

574

7 %

Share of Net Profit of Associates

10

17

(40) %

15

(31) %

44

57

(23) %

Profit Before Tax

(53)

67

NM

(46)

NM

(199)

142

NM

Tax

42

63

(33) %

53

(20) %

98

204

(52) %

Net Profit after Tax

(95)

4

NM

(99)

NM

(297)

(62)

NM

Exceptional item1

(41)

NM

NM

(20)

NM

Net Profit after Tax after Exceptional Item

(136)

4

NM

(99)

NM

(317)

(62)

NM

1. Q3FY26 – Includes gratuity and leave encashment provision due to impact of change in LWF Act  26 Crs. & Settlement with CDMO customers 15 Crs.
9MFY26 – Includes exceptional items of Q3FY26 partially offset by one time insolvency proceeds received in Q1FY26 from a claim filed against a third-
party supplier of CHG by  21Crs.

Q3 and 9M FY26 Earnings Conference Call

Piramal Pharma Limited will be hosting a conference call for investors / analysts on 29th January 2026 from 9:30 AM to 10:15 AM (IST) to discuss its Q3 and 9M FY26 Results.

The dial-in details for the call are as under:

Event

Location & Time

Telephone Number

Conference call on
29th January, 2026

India – 09:30 AM IST

+91 22 6280 1461 / +91 22 7115 8320 (Primary Number)

1 800 120 1221 (Toll free number)

USA – 11:00 AM

(Eastern Time – New York)

Toll free number

18667462133

UK – 04:00 AM

(London Time)

Toll free number

08081011573

Singapore – 12:00 PM

(Singapore Time)

Toll free number

8001012045

Hong Kong – 12:00 PM

(Hong Kong Time)

Toll free number

800964448

Express Join with Diamond Pass™

Please use this link for prior registration to reduce wait time at the time of joining the call –Click here

About Piramal Pharma Limited:

Piramal Pharma Limited (PPL), (NSE: PPLPHARMA) (BSE: 543635), offers a portfolio of differentiated products and services through its 171 global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and Piramal Consumer Healthcare (PCH) business, selling over-the-counter consumer and wellness products. In addition, one of PPL’s associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-therapeutics and vaccine segments.

For more information, visit: Piramal Pharma | LinkedIn

1. Includes one facility via PPL’s minority investment in Yapan Bio.

Logo: https://mma.prnewswire.com/media/1855206/Piramal_Pharma_Limited_Logo.jpg

Cision View original content:https://www.prnewswire.com/news-releases/piramal-pharma-limited-announces-results-for-q3-and-9m-fy26-302673563.html

SOURCE Piramal Pharma Limited

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

HitPaw API is Integrated by Comfy for Professional Image and Video Enhancement to Global Creators

HitPaw API is Integrated by Comfy for Professional Image and Video Enhancement to Global Creators

SAN FRANCISCO, Feb. 7, 2026 /PRNewswire/ — HitPaw, a leader in AI-powered visual enhancement solutions, announced Comfy, a global content creation platform, is
Share
AI Journal2026/02/08 09:15
Journalist gives brutal review of Melania movie: 'Not a single person in the theater'

Journalist gives brutal review of Melania movie: 'Not a single person in the theater'

A Journalist gave a brutal review of the new Melania documentary, which has been criticized by those who say it won't make back the huge fees spent to make it,
Share
Rawstory2026/02/08 09:08
Facts Vs. Hype: Analyst Examines XRP Supply Shock Theory

Facts Vs. Hype: Analyst Examines XRP Supply Shock Theory

Prominent analyst Cheeky Crypto (203,000 followers on YouTube) set out to verify a fast-spreading claim that XRP’s circulating supply could “vanish overnight,” and his conclusion is more nuanced than the headline suggests: nothing in the ledger disappears, but the amount of XRP that is truly liquid could be far smaller than most dashboards imply—small enough, in his view, to set the stage for an abrupt liquidity squeeze if demand spikes. XRP Supply Shock? The video opens with the host acknowledging his own skepticism—“I woke up to a rumor that XRP supply could vanish overnight. Sounds crazy, right?”—before committing to test the thesis rather than dismiss it. He frames the exercise as an attempt to reconcile a long-standing critique (“XRP’s supply is too large for high prices”) with a rival view taking hold among prominent community voices: that much of the supply counted as “circulating” is effectively unavailable to trade. His first step is a straightforward data check. Pulling public figures, he finds CoinMarketCap showing roughly 59.6 billion XRP as circulating, while XRPScan reports about 64.7 billion. The divergence prompts what becomes the video’s key methodological point: different sources count “circulating” differently. Related Reading: Analyst Sounds Major XRP Warning: Last Chance To Get In As Accumulation Balloons As he explains it, the higher on-ledger number likely includes balances that aggregators exclude or treat as restricted, most notably Ripple’s programmatic escrow. He highlights that Ripple still “holds a chunk of XRP in escrow, about 35.3 billion XRP locked up across multiple wallets, with a nominal schedule of up to 1 billion released per month and unused portions commonly re-escrowed. Those coins exist and are accounted for on-ledger, but “they aren’t actually sitting on exchanges” and are not immediately available to buyers. In his words, “for all intents and purposes, that escrow stash is effectively off of the market.” From there, the analysis moves from headline “circulating supply” to the subtler concept of effective float. Beyond escrow, he argues that large strategic holders—banks, fintechs, or other whales—may sit on material balances without supplying order books. When you strip out escrow and these non-selling stashes, he says, “the effective circulating supply… is actually way smaller than the 59 or even 64 billion figure.” He cites community estimates in the “20 or 30 billion” range for what might be truly liquid at any given moment, while emphasizing that nobody has a precise number. That effective-float framing underpins the crux of his thesis: a potential supply shock if demand accelerates faster than fresh sell-side supply appears. “Price is a dance between supply and demand,” he says; if institutional or sovereign-scale users suddenly need XRP and “the market finds that there isn’t enough XRP readily available,” order books could thin out and prices could “shoot on up, sometimes violently.” His phrase “circulating supply could collapse overnight” is presented not as a claim that tokens are destroyed or removed from the ledger, but as a market-structure scenario in which available inventory to sell dries up quickly because holders won’t part with it. How Could The XRP Supply Shock Happen? On the demand side, he anchors the hypothetical to tokenization. He points to the “very early stages of something huge in finance”—on-chain tokenization of debt, stablecoins, CBDCs and even gold—and argues the XRP Ledger aims to be “the settlement layer” for those assets.He references Ripple CTO David Schwartz’s earlier comments about an XRPL pivot toward tokenized assets and notes that an institutional research shop (Bitwise) has framed XRP as a way to play the tokenization theme. In his construction, if “trillions of dollars in value” begin settling across XRPL rails, working inventories of XRP for bridging, liquidity and settlement could rise sharply, tightening effective float. Related Reading: XRP Bearish Signal: Whales Offload $486 Million In Asset To illustrate, he offers two analogies. First, the “concert tickets” model: you think there are 100,000 tickets (100B supply), but 50,000 are held by the promoter (escrow) and 30,000 by corporate buyers (whales), leaving only 20,000 for the public; if a million people want in, prices explode. Second, a comparison to Bitcoin’s halving: while XRP has no programmatic halving, he proposes that a sudden adoption wave could function like a de facto halving of available supply—“XRP’s version of a halving could actually be the adoption event.” He also updates the narrative context that long dogged XRP. Once derided for “too much supply,” he argues the script has “totally flipped.” He cites the current cycle’s optics—“XRP is sitting above $3 with a market cap north of around $180 billion”—as evidence that raw supply counts did not cap price as tightly as critics claimed, and as a backdrop for why a scarcity narrative is gaining traction. Still, he declines to publish targets or timelines, repeatedly stressing uncertainty and risk. “I’m not a financial adviser… cryptocurrencies are highly volatile,” he reminds viewers, adding that tokenization could take off “on some other platform,” unfold more slowly than enthusiasts expect, or fail to get to “sudden shock” scale. The verdict he offers is deliberately bound. The theory that “XRP supply could vanish overnight” is imprecise on its face; the ledger will not erase coins. But after examining dashboard methodologies, escrow mechanics and the behavior of large holders, he concludes that the effective float could be meaningfully smaller than headline supply figures, and that a fast-developing tokenization use case could, under the right conditions, stress that float. “Overnight is a dramatic way to put it,” he concedes. “The change could actually be very sudden when it comes.” At press time, XRP traded at $3.0198. Featured image created with DALL.E, chart from TradingView.com
Share
NewsBTC2025/09/18 11:00